First Manhattan CO Crispr Therapeutics Ag Transaction History

First Manhattan CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$60.67 - $89.12 $46,715 - $68,622	770 Added 669.57%	885 $60,000
Q4 2023 Feb 13, 2024	SELL	$38.62 - $72.18 $6,449 - $12,054	-167 Reduced 59.22%	115 $7,000
Q3 2023 Nov 14, 2023	BUY	$45.39 - $59.0 $10,530 - $13,688	232 Added 464.0%	282 $12,000
Q1 2022 May 16, 2022	SELL	$53.19 - $79.24 $33,722 - $50,238	-634 Reduced 92.69%	50 $3,000
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $126,162 - $200,322	-1,800 Reduced 72.46%	684 $51,000
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $268,226 - $381,261	2,434 Added 4868.0%	2,484 $278,000
Q1 2021 May 14, 2021	SELL	$110.72 - $210.04 $33,216 - $63,012	-300 Reduced 85.71%	50 $6,000
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $3,983 - $8,661	50 Added 16.67%	350 $53,000
Q2 2018 Aug 01, 2018	BUY	$42.62 - $73.59 $12,786 - $22,077	300 New	300 $17,000

484

64.1M

1.64M

1.93M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.93B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.